Added to YB: 2026-09-21
Pitch date: 2026-09-17
KYTX [neutral]
Kyverna Therapeutics, Inc.
+1.57%
current return
Author Info
No bio for this author
Company Info
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.
Market Cap
$440.9M
Pitch Price
$7.02
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.80
P/E
-2.47
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Biotech Conferences Week 2 Day 3 Part 3 - Kyverna Therapeutics, Inc.
KYTX (quick overview): Kyverna is developing a fully human, CD28-costimulated autologous CD19 CAR-T for autoimmune disease, led by stiff-person syndrome, which has no approved therapies. Management cited pivotal KYSA-8 data showing a 46% improvement in timed walking, with over two-thirds of 12 device users reportedly no longer needing assistance by study end; BLA completion is targeted for Q4 2026. An approved platform could be strategically valuable, but follow-up must show treatment-free durability rather than a transient reset.
Read full article (2 min)